Episode
Episode 203 - Tim Noyes - CEO of Newleos Therapeutics
- Podcast
- The BioHub - by Avetix
- Published
- Jul 20, 2026
- Duration seconds
- 1574
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-203-tim-noyes-ceo-of-newleos-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-203-tim-noyes-ceo-of-newleos-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of The BioHub Podcast, Ben is joined by Tim Noyes, President and CEO of Newleos Therapeutics. Tim reflects on more than 35 years across the life sciences industry, from beginning his career at Merck to building and leading emerging biotechnology companies. He shares why he has consistently been drawn to smaller organisations, where leadership teams can remain close to the science, the patients and the people driving the company forward. The conversation explores Newleos’ mission to rethink the treatment of anxiety and other neuropsychiatric conditions through a pipeline of differentiated GABA-A receptor modulators originally licensed from Roche. Tim discusses the opportunity to retain the therapeutic benefits associated with GABA modulation while overcoming the limitations of traditional benzodiazepines, including the company’s clinical programmes in generalised anxiety disorder and social anxiety disorder. They also discuss the importance of patient access, the challenges of reimbursement in the US healthcare system, and why humility, appreciation and a people-focused culture are central to Tim’s approach to leadership.